Primary Myelofibrosis Market Report 2026

Primary Myelofibrosis Market Overview

• Primary Myelofibrosis market size has reached to $0.84 billion in 2025 • Expected to grow to $1.14 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: The Increasing Prevalence Of Myelofibrosis Is Fueling The Market Due To Its High Occurrence Among The Aging Population • Market Trend: JAK2 Inhibitor Innovations Driving Growth In The Market Due To Enhanced Symptom Control And Disease Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Primary Myelofibrosis Market?

Primary myelofibrosis (PMF) is a rare, chronic bone marrow disorder characterized by the excessive formation of fibrous scar tissue (fibrosis) within the bone marrow. This fibrosis disrupts normal blood cell production, leading to anemia, weakness, fatigue, and an enlarged spleen (splenomegaly). PMF is a type of myeloproliferative neoplasm (MPN) and can cause symptoms such as night sweats, weight loss, and bone pain. The main types of primary myelofibrosis are spinocerebellar primary myelofibrosis, primary myelofibrosis-telangiectasia, episodic primary myelofibrosis, and other types. Services include treatment and diagnosis, while medications are available in various dosage forms such as solids, liquids, and other formulations to address diverse patient needs. The disease affects all age groups, including adults, children, and geriatric patients, and is treated across various end users, such as hospitals, clinics, and other healthcare settings.

What Is The Primary Myelofibrosis Market Growth Forecast?

The primary myelofibrosis market size is expected to see strong growth in the next few years. It will grow to $1.14 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to development of novel targeted therapies, increasing clinical trial activities, advancements in genetic and molecular diagnostics, growing investment in hematology research, rising adoption of personalized medicine. Major trends in the forecast period include rising awareness and early diagnosis of primary myelofibrosis, growth in targeted therapies and personalized treatment approaches, increased adoption of advanced diagnostic tools, expansion of clinical trials and research activities, focus on patient support programs and disease management.

Global Primary Myelofibrosis Market Segmentation

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types 2) By Services: Treatment, Diagnosis 3) By Dosage Forms: Solid, Liquids, Other Dosage Forms 4) By Age: Adult, Child, Geriatric 5) By End User: Hospitals, Clinics, Other End Users Subsegments: 1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations 2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis 3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders 4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

What Is The Driver Of The Primary Myelofibrosis Market?

The increasing prevalence of myelofibrosis is expected to propel the growth of the primary myelofibrosis market going forward. Myelofibrosis refers to a rare type of bone marrow cancer that disrupts the body's normal production of blood cells, leading to extensive scarring in the bone marrow and resulting in severe anemia, weakness, fatigue, and an enlarged spleen. The increasing prevalence of myelofibrosis is primarily due to the aging population, as the condition most commonly affects individuals over the age of 60, and longer life expectancy is contributing to a higher number of diagnosed cases. The rising prevalence of myelofibrosis improves the management of primary myelofibrosis by driving research, enhancing early diagnosis, increasing treatment options, and promoting better clinical guidelines and specialized care. For instance, in November 2024, according to the report published by the National Institute for Health and Care Excellence, a UK-based independent executive non-departmental public body, myelofibrosis has a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. Therefore, the increasing prevalence of myelofibrosis is driving the growth of the primary myelofibrosis industry.

Key Players In The Global Primary Myelofibrosis Market

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Global Primary Myelofibrosis Market Trends and Insights

Major companies operating in the primary myelofibrosis market are focusing on developing innovative products such as Janus kinase 2 inhibiting tablets to improve symptom control and slow disease progression. Janus kinase 2 (JAK2) inhibiting tablets are oral medications that block the activity of the JAK2 enzyme, which is involved in the abnormal signaling pathways that cause excessive blood cell production in primary myelofibrosis. These tablets help reduce spleen size, alleviate fatigue and bone pain symptoms, and slow disease progression. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, launched Omjjara (momelotinib), a new treatment for myelofibrosis. It is approved by South Korea’s Ministry of Food and Drug Safety and intended for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara is an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), effectively addressing symptoms such as anemia, enlarged spleen, and fatigue. Its approval is supported by clinical trial data demonstrating significant improvements in anemia, spleen size, and overall symptoms compared to existing treatments.

What Are Latest Mergers And Acquisitions In The Primary Myelofibrosis Market?

In September 2025, GlaxoSmithKline plc (GSK), a UK-based biopharmaceutical company, partnered with the pan-Canadian Pharmaceutical Alliance (pCPA) to advance public access for Ojjaara in Canada. With this partnership, the LOI aims to facilitate reimbursement and improve availability of Ojjaara for the treatment of adults with myelofibrosis who have moderate to severe anemia. The pan-Canadian Pharmaceutical Alliance (pCPA) is a Canada-based collaborative drug-pricing and negotiation body representing provincial and territorial public drug plans.

Regional Insights

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Primary Myelofibrosis Market?

The primary myelofibrosis market consists of revenues earned by entities by providing services such as diagnosis services, medical consultations, treatment services, monitoring and follow-up and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary myelofibrosis (PMF) market also includes sales of products including ruxolitinib (Jakafi or Jakavi), erythropoiesis-stimulating agents (ESAs), hydroxyurea, bone marrow or stem cell transplant kits and iron supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Primary Myelofibrosis Market Report 2026?

The primary myelofibrosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the primary myelofibrosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.